Insider Selling: 1Life Healthcare, Inc. (NASDAQ:ONEM) Director Sells $457,286.58 in Stock

1Life Healthcare, Inc. (NASDAQ:ONEM) Director David P. Kennedy sold 8,334 shares of the stock in a transaction that occurred on Thursday, February 18th. The shares were sold at an average price of $54.87, for a total value of $457,286.58. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

1Life Healthcare stock opened at $56.67 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 7.40 and a quick ratio of 7.35. The company has a market capitalization of $7.54 billion and a PE ratio of -31.48. 1Life Healthcare, Inc. has a one year low of $15.00 and a one year high of $59.82. The business has a 50 day simple moving average of $49.56 and a 200 day simple moving average of $36.44.

Get 1Life Healthcare alerts:

Institutional investors have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC bought a new position in shares of 1Life Healthcare during the 3rd quarter worth approximately $55,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of 1Life Healthcare by 126.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,160 shares of the company’s stock worth $61,000 after buying an additional 1,207 shares during the period. Trustcore Financial Services LLC lifted its position in shares of 1Life Healthcare by 14,428.6% during the 3rd quarter. Trustcore Financial Services LLC now owns 3,051 shares of the company’s stock worth $87,000 after buying an additional 3,030 shares during the period. CWM LLC lifted its position in shares of 1Life Healthcare by 28.4% during the 4th quarter. CWM LLC now owns 2,260 shares of the company’s stock worth $99,000 after buying an additional 500 shares during the period. Finally, International Assets Investment Management LLC bought a new position in shares of 1Life Healthcare during the 4th quarter worth approximately $111,000. Institutional investors and hedge funds own 76.75% of the company’s stock.

Several analysts recently weighed in on ONEM shares. BTIG Research started coverage on 1Life Healthcare in a research note on Wednesday, January 6th. They set a “neutral” rating for the company. Credit Suisse Group increased their target price on 1Life Healthcare from $37.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 11th. Zacks Investment Research downgraded 1Life Healthcare from a “hold” rating to a “sell” rating in a research note on Wednesday, February 3rd. Smith Barney Citigroup increased their target price on 1Life Healthcare from $38.00 to $42.00 in a research note on Wednesday, November 11th. Finally, Morgan Stanley increased their target price on 1Life Healthcare from $35.00 to $41.00 and gave the company an “overweight” rating in a research note on Wednesday, November 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $41.86.

1Life Healthcare Company Profile

1Life Healthcare, Inc operates a membership-based primary care platform. The company has developed a healthcare membership model based on direct consumer enrollment, as well as employer sponsorship. Its membership model includes seamless access to digital health services paired with inviting in-office care routinely covered under health insurance programs.

Recommended Story: What does a bar chart display?

Receive News & Ratings for 1Life Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 1Life Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.